review Open AccessTop 1% cited
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Nature reviews. Cancer · 2019 · Vol. 19(3) · pp. 133–150
Jonathan J. Havel✉(Memorial Sloan Kettering Cancer Center)Diego Chowell(Memorial Sloan Kettering Cancer Center)Timothy A. Chan(Memorial Sloan Kettering Cancer Center)
Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology ResearchLung Cancer Research StudiesImmunotherapyImmune checkpointTumor microenvironmentCancer immunotherapyBiologyComputational biologyImmune systemCytotoxic T cellCancer researchImmunology
MeSH terms
AnimalsHumansImmunologic FactorsImmunotherapyNeoplasmsTumor MicroenvironmentB7-H1 AntigenCTLA-4 Antigen
Citations
2,306
FWCI
144.10
field-weighted impact
References
261
Percentile
100%
vs. same field & year
Citations per year
Cited by
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Frontiers in Immunology · 2020 · 628 citations
Cancer immunotherapy: Pros, cons and beyond
Biomedicine & Pharmacotherapy · 2020 · 669 citations
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
British Journal of Cancer · 2020 · 1,613 citations
Macrophages as tools and targets in cancer therapy
Nature Reviews Drug Discovery · 2022 · 1,634 citations
References
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Oncotarget · 2015 · 322 citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Immunity · 2013 · 4,641 citations
Tumor-Associated Macrophages: From Mechanisms to Therapy
Immunity · 2014 · 3,967 citations
Signatures of Environmental Genetic Adaptation Pinpoint Pathogens as the Main Selective Pressure through Human Evolution
PLoS Genetics · 2011 · 607 citations
Robust enumeration of cell subsets from tissue expression profiles
Nature Methods · 2015 · 13,801 citations
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Cancer Research · 2014 · 1,264 citations
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.